Farmacogenetica
Studio delle varianti genetiche che influenzano la risposta ai trattamenti farmacologici.
Avanzato test genetico che permette di prevedere la risposta del paziente ai particolare farmaci. I clinici potranno utilizzare l’informazione derivante dal test per personalizzare la terapia in base al profilo genetico del paziente, individuando il farmaco più appropriato e il relativo dosaggio ottimale, evitando il lungo processo di adattamento della terapia e il rischio di tossicità.
Gene Count | List of genes | Notes |
---|---|---|
18 | CHE, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, G6PD, HLA-B, IFNL4, NAT2, NUDT15, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1 | Pharmacogenetic (PGx) tests gives clinicians the tools to better understand
how their patients will respond to certain medications. With PGx testing, it’s
possible to tailor medication plans to a patient’s specific genetic makeup. This
can lead to reduced medical costs for patients and providers, safer medication
plans, and more efficient drug efficacy. The PGx Focus Panel includes genes
associated with drug metabolism with high-level evidence and clinically
actionable guidelines. PGx testing can reveal if a person is a fast, normal, or slow metabolizer. A person’s metabolism changes the way their body responds to medication, including: • Toxicity Excessive amounts of the drug accumulate in the bloodstream, resulting in ADRs. • Lack of Efficacy The bloodstream cannot absorb enough of the drug to achieve a therapeutic effect. • Hypersensitivity Normal amounts of the drug enter the bloodstream, but even this is enough to trigger severe reactions in people with hypersensitivity to the medication. Potential benefits for patients Identify which drug may be most effective before treatment starts PGx testing can help clinicians choose the most effective drug for each patient, minimize the risk of adverse reactions, and reduce hospitalizations. Reduce the risk of adverse events related to certain drugs PGx testing can assess a patient’s risk for adverse drug reactions before they take the medication which can improve patient safety and minimize costs for healthcare facilities. Adjust and optimize the dose of current medications PGx testing can help clinicians predict the appropriate dose of medication for their patient. This allows them to create more personalized medication plans to maximize efficacy and reduce pharmacy costs. Improved Patient Care PGx test results become part of a patient’s medical record, allowing physicians to make more informed decisions when prescribing medications for future medical issues. |
Gene Count | List of genes | Notes |
---|---|---|
44 | ABCB1, ACE, ANKK1, APOE, ATM, BCHE, CES1, COMT, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, ERCC1, F2, F5, G6PD, GGCX, GRIK4, GSTP1, HLA-B, HTR1A, HTR2A, HTR2C, IFNL4, ITPA, KIF6, MTHFR, NAT2, NQO1, NUDT15, OPRM1, RYR1, SLCO1B1, TPMT, UGT1A1, UGT1A4, VKORC1, XRCC1 | Pharmacogenetic (PGx) tests gives clinicians the tools to better understand
how their patients will respond to certain medications. With PGx testing, it’s possible to tailor medication plans to a patient’s specific genetic makeup. This can lead to reduced medical costs for patients and providers, safer medication plans, and more efficient drug efficacy. The PGx Comprehensive Panel includes genes associated with drug metabolism with high level evidence and clinically actionable guidelines, in addition to genes with PharmGKB evidence of 2 or higher. Evidence for these associations are significant, but not as high as those in the focused panel. PGx testing can reveal if a person is a fast, normal, or slow metabolizer. A person’s metabolism changes the way their body responds to medication, including: • Toxicity Excessive amounts of the drug accumulate in the bloodstream, resulting in ADRs. • Lack of Efficacy The bloodstream cannot absorb enough of the drug to achieve a therapeutic effect. • Hypersensitivity Normal amounts of the drug enter the bloodstream, but even this is enough to trigger severe reactions in people with hypersensitivity to the medication. Potential benefits for patients Identify which drug may be most effective before treatment starts PGx testing can help clinicians choose the most effective drug for each patient, minimize the risk of adverse reactions, and reduce hospitalizations. Reduce the risk of adverse events related to certain drugs PGx testing can assess a patient’s risk for adverse drug reactions before they take the medication which can improve patient safety and minimize costs for healthcare facilities. Adjust and optimize the dose of current medications PGx testing can help clinicians predict the appropriate dose of medication for their patient. This allows them to create more personalized medication plans to maximize efficacy and reduce pharmacy costs. Improved Patient Care PGx test results become part of a patient’s medical record, allowing physicians to make more informed decisions when prescribing medications for future medical issues. |
Gene Count | List of genes | Notes |
---|---|---|
4 | CYP2C9, CYP2D6, CYP2C19, VKORC1 | An advanced genetic test that allows to predict the patient's response to
particular drugs. Clinicians will be able to use the information deriving from
the test to customize the therapy based on the patient's genetic profile,
identifying the most appropriate drug and its optimal dosage, avoiding the long
process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
5 | CYP1A2, CYP2C9, CYP2C19, CYP2D6, 5HTT | An advanced genetic test that allows to predict the patient's response to
particular drugs. Clinicians will be able to use the information deriving from
the test to customize the therapy based on the patient's genetic profile,
identifying the most appropriate drug and its optimal dosage, avoiding the long
process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
3 | CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
25 | ABCC2 (Metabolism methotrexate), ABCB1 (Metabolism taxan derived drugs), ABL, ADRB2, CYP3A4 (Metabolism taxan derived drugs), CYP3A5 (Metabolism taxan derived drugs), DPYD (Metabolism FLUOROPYRIMIDINES drugs), EGFR, ERCC1 (Metabolism platinum derived drugs), FLT3, GSTP1, GSTP1 (Metabolism platinum derived drugs), KIT, MDR1, PDGFRA, RAD51, TPMT, TS, TSER (Metabolism FLUOROPYRIMIDINES drugs), UGT1A1, UGT1A6, UGT1A7, UGT1A9, XRCC1 (Metabolism platinum derived drugs), XRCC3. | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
5 | ABCC2 (Metabolism methotrexate), ABCB1 (Metabolism taxan derived drugs), ABL, ADRB2, CYP3A4 (Metabolism taxan derived drugs), CYP3A5 (Metabolism taxan derived drugs), DPYD (Metabolism FLUOROPYRIMIDINES drugs), EGFR, ERCC1 (Metabolism platinum derived drugs), FLT3, GSTP1, GSTP1 (Metabolism platinum derived drugs), KIT, MDR1, PDGFRA, RAD51, TPMT, TS, TSER (Metabolism FLUOROPYRIMIDINES drugs), UGT1A1, UGT1A6, UGT1A7, UGT1A9, XRCC1 (Metabolism platinum derived drugs), XRCC3. | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
5 | CYP1A2, CYP2C9, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
4 | CYP2D6, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
3 | GSTP1, XRCC1, ERCC1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
3 | TYMS, DPD, MTHFR | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
4 | ABCB1, CBR3, SOD2, GSTM1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
1 | ACYP2D6 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
4 | UGT1A, CYP3A4, CYP3A5, ABCB1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
3 | MTHFR, TYMS, ABCC2 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
4 | XRCC1, XRCC3, RAD51, GSTP1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
3 | CYP3A4, CYP3A5, ABCB1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
7 | CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
6 | CYP1A2, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity.. |
Gene Count | List of genes | Notes |
---|---|---|
7 | CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
1 | DRD2 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
5 | CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |
Gene Count | List of genes | Notes |
---|---|---|
10 | CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7, A2M, COMT, DRD2, FLT3, MDR1 | An advanced genetic test that allows to predict the patient's response to particular drugs. Clinicians will be able to use the information deriving from the test to customize the therapy based on the patient's genetic profile, identifying the most appropriate drug and its optimal dosage, avoiding the long process of adapting the therapy and the risk of toxicity. |